BACKGROUND: Screening for fecal occult blood can be effective in reducing colorectal cancer mortality only if positive tests are appropriately followed up with complete diagnostic evaluation (ie, colonoscopy or flexible sigmoidoscopy with double contrast barium enema) and treatment. OBJECTIVES: To examine whether rates of complete diagnostic evaluation after a positive fecal occult blood test (FOBT) have improved over time after the implementation of tracking systems and physician guidelines within a large integrated health care organization. RESEARCH DESIGN: From 1993 to 2005, 8513 positive FOBTs were identified on 8291 enrollees aged 50-79 of a large health care system. Automated records were used to identify repeat FOBTs, colonoscopy, flexible sigmoidoscopy, and double-contrast barium enema within 1 year after the positive FOBT. National rates of complete diagnostic evaluation were estimated from the 2005 National Health Interview Survey. RESULTS: In this integrated health care organization, the percentage of positive FOBTs followed by complete diagnostic evaluation within 1 year increased from 57-64% in 1993-1996 to 82-86% from 2000-2005. Use of repeat FOBT after a positive FOBT decreased from 28-31% in 1993-1996 to 6-11% in 2000-2005. Based on the National Health Interview Survey, only 52% of positive FOBTs in 2000-2005 were followed by complete diagnostic evaluation nationally. CONCLUSIONS: Adherence to recommendations for complete diagnostic evaluation after a positive FOBT has greatly improved over time in an integrated group medical practice. Through the use of tracking systems and screening guidelines, it may be possible to reach levels of follow-up that are comparable to those observed in randomized trials.
BACKGROUND: Screening for fecal occult blood can be effective in reducing colorectal cancer mortality only if positive tests are appropriately followed up with complete diagnostic evaluation (ie, colonoscopy or flexible sigmoidoscopy with double contrast barium enema) and treatment. OBJECTIVES: To examine whether rates of complete diagnostic evaluation after a positive fecal occult blood test (FOBT) have improved over time after the implementation of tracking systems and physician guidelines within a large integrated health care organization. RESEARCH DESIGN: From 1993 to 2005, 8513 positive FOBTs were identified on 8291 enrollees aged 50-79 of a large health care system. Automated records were used to identify repeat FOBTs, colonoscopy, flexible sigmoidoscopy, and double-contrast barium enema within 1 year after the positive FOBT. National rates of complete diagnostic evaluation were estimated from the 2005 National Health Interview Survey. RESULTS: In this integrated health care organization, the percentage of positive FOBTs followed by complete diagnostic evaluation within 1 year increased from 57-64% in 1993-1996 to 82-86% from 2000-2005. Use of repeat FOBT after a positive FOBT decreased from 28-31% in 1993-1996 to 6-11% in 2000-2005. Based on the National Health Interview Survey, only 52% of positive FOBTs in 2000-2005 were followed by complete diagnostic evaluation nationally. CONCLUSIONS: Adherence to recommendations for complete diagnostic evaluation after a positive FOBT has greatly improved over time in an integrated group medical practice. Through the use of tracking systems and screening guidelines, it may be possible to reach levels of follow-up that are comparable to those observed in randomized trials.
Authors: H M Shields; M S Weiner; D R Henry; J A Lloyd; B J Ransil; D A Lamphier; D W Gallagher; D A Antonioli; B A Rosner Journal: Am J Gastroenterol Date: 2001-01 Impact factor: 10.864
Authors: Holly L Howe; Xiaocheng Wu; Lynn A G Ries; Vilma Cokkinides; Faruque Ahmed; Ahmedin Jemal; Barry Miller; Melanie Williams; Elizabeth Ward; Phyllis A Wingo; Amelie Ramirez; Brenda K Edwards Journal: Cancer Date: 2006-10-15 Impact factor: 6.860
Authors: Nadeem Baig; Ronald E Myers; Barbara J Turner; James Grana; Todd Rothermel; Neil Schlackman; David S Weinberg Journal: Am J Gastroenterol Date: 2003-09 Impact factor: 10.864
Authors: Ronald E Myers; Barbara Turner; David Weinberg; Terry Hyslop; Walter W Hauck; Timothy Brigham; Todd Rothermel; James Grana; Neil Schlackman Journal: Prev Med Date: 2004-04 Impact factor: 4.018
Authors: Ann Oluloro; Amanda F Petrik; Ann Turner; Tanya Kapka; Jennifer Rivelli; Patricia A Carney; Somnath Saha; Gloria D Coronado Journal: J Community Health Date: 2016-08
Authors: Beverly B Green; C Y Wang; Kathryn Horner; Sheryl Catz; Richard T Meenan; Sally W Vernon; David Carrell; Jessica Chubak; Cynthia Ko; Sharon Laing; Andy Bogart Journal: Contemp Clin Trials Date: 2010-07-30 Impact factor: 2.226
Authors: Melissa R Partin; Amy A Gravely; James F Burgess; David A Haggstrom; Sarah E Lillie; David B Nelson; Sean M Nugent; Aasma Shaukat; Shahnaz Sultan; Louise C Walter; Diana J Burgess Journal: Cancer Date: 2017-05-11 Impact factor: 6.860
Authors: Anne Marie McCarthy; Jane J Kim; Elisabeth F Beaber; Yingye Zheng; Andrea Burnett-Hartman; Jessica Chubak; Nirupa R Ghai; Dale McLerran; Nancy Breen; Emily F Conant; Berta M Geller; Beverly B Green; Carrie N Klabunde; Stephen Inrig; Celette Sugg Skinner; Virginia P Quinn; Jennifer S Haas; Mitchell Schnall; Carolyn M Rutter; William E Barlow; Douglas A Corley; Katrina Armstrong; Chyke A Doubeni Journal: Am J Prev Med Date: 2016-04-28 Impact factor: 5.043
Authors: Rebecca A Hubbard; Eric Johnson; Raymond Hsia; Carolyn M Rutter Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07-18 Impact factor: 4.254